| Literature DB >> 34789490 |
Igor C Johansen1, Priscila T Rodrigues1, Juliana Tonini1, Joseph Vinetz2, Marcia C Castro3, Marcelo U Ferreira4.
Abstract
PURPOSE: This population-based open cohort study aims to investigate biological and sociodemographic drivers of malaria transmission in the main urban hotspot of Amazonian Brazil. PARTICIPANTS: Nearly 20% of the households in the northwestern town of Mâncio Lima were randomly selected and 2690 participants were enrolled since April 2018. Sociodemographic, housing quality, occupational, behavioural and morbidity information and travel histories were collected during consecutive study visits. Blood samples from participants>3 months old were used for malaria diagnosis and human genetic studies; samples from participants with laboratory-confirmed malaria have been cryopreserved for genetic and phenotypic characterisation of parasites. Serology was introduced in 2020 to measure the prevalence and longevity of SARS-CoV-2 IgG antibodies. FINDINGS TO DATE: Malaria prevalence rates were low (up to 1.0% for Plasmodium vivax and 0.6% for P. falciparum) during five consecutive cross-sectional surveys between April-May 2018 and October-November 2020; 63% of infections diagnosed by microscopy were asymptomatic. Malaria risk is heterogeneously distributed, with 20% study participants contributing 86% of the overall burden of P. vivax infection. Adult males are at greatest risk of infection and human mobility across the urban-rural interface may contribute to sustained malaria transmission. Local P. vivax parasites are genetically diverse and fragmented into discrete inbred lineages that remain stable across space and time. FUTURE PLANS: Two follow-up visits, with similar study protocols, are planned in 2021. We aim to identify high-risk individuals that fuel onwards malaria transmission and represent a priority target for more intensive and effective control interventions. TRIAL REGISTRATION NUMBER: NCT03689036. © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Entities:
Keywords: epidemiology; parasitology
Mesh:
Year: 2021 PMID: 34789490 PMCID: PMC8727682 DOI: 10.1136/bmjopen-2020-048073
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1Participant flow chart of the Mâncio Lima cohort study of urban malaria.
Data collected for the Mâncio Lima cohort study of urban malaria
| Measures | Description |
| Questionnaire data | |
| Demographic | Age; gender; pregnancy status; birthplace; literacy; |
| Socioeconomic |
|
| Occupational | Individual work status (does not work; formal employee; informal employee; employer) |
| Behavioural | Regular fishing (no/yes); sleeping by the river (no/yes); sleeps with open or closed window (no/yes); time that go to bed and wake up; bathing inside or outside the house; use of bed nets during the night before interview. |
| Travel history | Overnight trip outside the town since the last follow-up visit (no/yes, place most frequently visited and duration of stay) |
| Morbidity | Laboratory-diagnosed malaria since the last follow-up visit (how many positive diagnosis and parasite species); malaria symptoms in the 7 days prior to the interview |
| Laboratory data | |
| Malaria microscopy | Giemsa-stained thick smears |
| Malaria RDT | QuickProfile Pf/Pv immunochromatographic test (LumiQuick, Santa Clara, USA). |
| Malaria PCR | Genus-specific quantitative PCR protocol that targets the mitochondrial genome followed by species-specific amplification |
| Duffy/DARC genotyping | TaqMan assays (Applied Biosystems, Foster City, USA) to genotype rs2814778 and rs12075 |
| CYP2D6 genotyping | TaqMan assays (Applied Biosystems) to genotype 12 CYP2D6 single nucleotide polymorphisms and quantify |
| SARS-CoV-2 antibodies | ELISA for IgG antibodies to the recombinant subdomain S1 of the SARS-CoV-2 spike protein (EI 2606–9601 G; Euroimmun, Lübeck, Germany) |
| Dengue antibodies | ELISA for IgG antibodies to dengue virus serotype 2 viral particles (EI 266b-9601 G; Euroimmun, Lübeck, Germany) |
| Parasite phenotypes | Ex-vivo assays of drug sensitivity and red blood cell invasion |
| Parasite genome sequencing | Whole-genome sequencing on an Illumina NovaSeq next-generation sequencer |
*Household-level variables are underlined.
RDT, rapid diagnostic test.
Timeline of measurements for the Mâncio Lima cohort study of urban malaria
| Variables | Census survey | Visit 1 | Visit 2 | Visit 3 | Visit 4 | Visit 5 |
| Questionnaire data | ||||||
| No participants interviewed | 9124 | 1394 | 2009 | 2017 | 2130 | 2074 |
| Demographic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Socioeconomic | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Occupational | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Behavioural | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Clinical | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Travel history | ✓ | ✓ | ✓ | |||
| Laboratory data | ||||||
| No blood samples collected* | 1082 | 1696 | 1578 | 1768 | 1677 | |
| Malaria microscopy | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Malaria RDT | ✓ | ✓ | ✓ | ✓ | ||
| Malaria PCR | ✓ | ✓ | ✓ | ✓ | ✓ | |
| Duffy/DARC genotyping | ✓ | ✓ | ✓ | ✓ | ✓ | |
| CYP2D6 genotyping | ✓ | ✓ | ✓ | ✓ | ✓ | |
| SARS-CoV-2 antibodies | ✓ | |||||
| Dengue antibodies | ✓ | ✓ | ||||
| Malaria parasite sequencing and phenotyping† | ✓ | ✓ | ✓ | ✓ | ✓ |
✓denotes that the measurement has been made at the noted study visit.
*Finger-prick capillary blood samples collected for malaria diagnosis were used for human genetic and SARS-CoV-2 studies.
†Venous blood samples were collected from consenting study participants with laboratory-confirmed malaria and leucocyte depleted for whole-genome sequencing and ex-vivo phenotypic assays.
RDT, rapid diagnostic test.
Number of malarial infections diagnosed by rapid diagnostic test (RDT) and conventional microscopy, according to the presence of malaria-related symptoms, during five consecutive cross-sectional surveys in the Mâncio Lima, cohort (2018–2020)
| Symptoms | Species | Study visit | |||||||||
| 1 | 2 | 3 | 4 | 5 | |||||||
| RDT | Microscopy | RDT | Microscopy | RDT | Microscopy | RDT | Microscopy | RDT | Microscopy | ||
| Yes |
| – | 3 | 4 | 0 | 0 | 3 | 1 | 1 | 0 | 0 |
|
| – | 2 | 4 | 8 | 2 | 4 | 0 | 0 | 0 | 2 | |
| Mixed | – | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | |
| No. tested | – | 218 | 307 | 308 | 182 | 182 | 205 | 205 | 137 | 137 | |
| No |
| – | 5 | 4 | 3 | 3 | 3 | 3 | 1 | 0 | 1 |
|
| – | 12 | 5 | 5 | 2 | 5 | 3 | 3 | 0 | 1 | |
| Mixed | – | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | |
| No. tested | – | 864 | 1389 | 1388 | 1396 | 1396 | 1563 | 1563 | 1540 | 1540 | |
| Total |
| – | 8 | 8 | 3 | 3 | 6 | 4 | 2 | 0 | 1 |
|
| – | 14 | 9 | 13 | 4 | 9 | 3 | 3 | 0 | 3 | |
| Mixed | – | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | |
| No. tested | – | 1082 | 1696 | 1696 | 1578 | 1578 | 1768 | 1768 | 1677 | 1677 | |
| Prevalence (%) |
| – | 0.6 | 0.4 | 0.1 | 0.1 | 0.3 | 0.2 | 0.1 | 0.0 | 0.0 |
|
| – | 1.0 | 0.4 | 0.6 | 0.2 | 0.4 | 0.1 | 0.1 | 0.0 | 0.1 | |
| Mixed | – | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
Dates of study visits: 1, April–May 2018; 2, September–October 2018; 3, May–June 2019; 4, September–October 2019; and 5, October–November 2020. Symptoms (at least one present within the past 2 weeks): fever, chills, sweating, headache, nausea, vomiting, myalgia and arthralgia.